271 results on '"Ailawadhi S"'
Search Results
2. 209MO Impact of CMV reactivation on survival and relapse following allogeneic stem cell transplantation for de novo myeloid sarcoma
3. Real-World Utilization of Radiation Therapy (RT) in Multiple Myeloma (MM): An Analysis of the Connect® MM Registry
4. P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
5. S171: MOLECULAR CLUSTERS OF IGM MONOCLONAL GAMMOPATHIES PRESENT DISTINCT BIOLOGIC, IMMUNE AND METABOLIC FEATURES
6. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
7. Management of Lytic Bone Disease in Lymphoplasmacytic Lymphoma: A Case Report and Review of the Literature
8. Financial burden after allogeneic hematopoietic cell transplantation: a qualitative analysis from the patient’s perspective
9. 857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)
10. Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management
11. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
12. P1.12-08 The Impact of Patient Age and Socioeconomic Factors on Clinical Outcomes in Small Cell Lung Cancer (SCLC): A National Study
13. 16-01 Efficacité et tolérance de l’administration hebdomadaire versus bihebdomadaire de carfilzomib en association à la dexaméthasone: analyse en sous-groupes de l’étude de phase 3 ARROW en fonction du nombre de lignes de traitement antérieures
14. Serotonin syndrome caused by interaction between citalopram and fentanyl
15. PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY
16. P1.15-18 The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study
17. P2.06-24 The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA
18. Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry
19. OA 06.07 Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers
20. OA 06.05 Socioeconomic Factors Affecting Outcomes in Non-Small Cell Lung Cancer (NSCLC): A Large Population-Based Analysis
21. Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
22. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
23. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
24. 1007O - Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry
25. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
26. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
27. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
28. Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
29. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
30. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).
31. Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting—Does it matter? A single institution experience
32. Intestinal Trefoil Factor (TFF3) expression and correlation with other signalling proteins in cholangiocarcinoma
33. Carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer receiving systemic chemotherapy
34. Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer.
35. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.
36. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
37. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
38. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
39. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.
40. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.
41. Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.
42. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect Ⓡ MM Registry.
43. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
44. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.
45. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.
46. Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
47. Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.
48. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
49. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
50. MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.